

## Myobloc® (rimabotulinumtoxinB)

When requesting Myobloc® (rimabotulinumtoxinB), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines for the covered indications.

### FDA-approved Indications

- Treatment of adults with cervical dystonia.
- Treatment of adults with chronic sialorrhea.

### Coverage Guidelines

#### Cervical Dystonia

The individual must meet **all** of the following criteria for approval:

- Has failed or developed a tolerance to Botox® (onabotulinumtoxinA); AND
- Is 18 years of age or older.

#### Chronic Sialorrhea

The individual must have a diagnosis of chronic sialorrhea and be 18 years of age or older for approval.

**Approval duration: 12 months**

### Recommended Dosing

#### Cervical Dystonia

Approve up to a maximum dose of 5000 units, divided among affected muscles, no more frequently than once every 12 weeks.

#### Chronic Sialorrhea

Approve up to a maximum dose of 3,500 units, divided among the parotid and submandibular glands, no more frequently than once every 12 weeks.

### References

1. Myobloc® (rimabotulinumtoxinB) [prescribing information]. South San Francisco, CA: Solstice Neurosciences, Inc.: August 2019. Accessed October 30, 2019.
2. Myobloc® (rimabotulinumtoxinB). Ln: DRUGDEX System Micromedex. Greenwood Village, CO: Thompson Reuters (Healthcare) Inc. [Updated September 03, 2019; Accessed October 30, 2019]
3. Simpson, DN et al. Practice guideline update summary. Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology. 2016; 86(19):1818-1826.